Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | PNMT | P11086 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | BAD | Q92934 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29760433 | 1.00 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL29365985 | 0.95 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL10328388 | 0.95 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL31011759 | 0.93 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11247615 | 0.85 | — | — | |
| SCHEMBL18647408 | 0.81 | BCL2L1 (0.42) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11005863 | 0.81 | CYP2A6 (0.47) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL12430508 | 0.80 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL11005936 | 0.77 | TSHR (0.44) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL29292684 | 0.77 | PNMT (0.39) | ADRA2AADRA2BADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0094146-B1 | ANTIFUNGAL AZOLYL PHENYL SUBSTITUTED ALICYCLIC ALCOHOLS | ZENECA LIMITED (GB) | 1987-01-14 | — | — | EP | claimed |
| EP-0094146-A1 | Antifungal azolyl phenyl substituted alicyclic alcohols | ZENECA LIMITED (GB) | 1983-11-16 | — | — | EP | claimed |
| US-20240101560-A1 | NITROGENOUS HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2024-03-28 | — | — | US | disclosed |
| EP-3423431-B1 | CARBAMATE DERIVATIVE COMPOUNDS AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2023-11-29 | — | — | EP | disclosed |
| CN-116649013-A | Nitrogen-containing heteroaromatic compounds for organic electroluminescent devices | 默克专利有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-10961396-B2 | Methine dyes | LANXESS DEUTSCHLAND GMBH (DE) | 2021-03-30 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190112485-A1 | NOVEL METHINE DYES | LANXESS DEUTSCHLAND GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| CN-107835800-A | cyclic compound | 武田药品工业株式会社 | 2018-03-23 | — | — | CN | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-2172470-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008019124-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007092213-A2 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
| EP-0094146-B1 | ANTIFUNGAL AZOLYL PHENYL SUBSTITUTED ALICYCLIC ALCOHOLS | ZENECA LIMITED (GB) | 1987-01-14 | — | — | EP | disclosed |
| US-4503062-A | PLANT FUNGICIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-03-05 | — | — | US | disclosed |
| EP-0094146-A1 | Antifungal azolyl phenyl substituted alicyclic alcohols | ZENECA LIMITED (GB) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112485-A1 | NOVEL METHINE DYES | TET1, TET3, PRMT5 | ADRA2A 3549/4885ADRA2B 3830/4885ADRA2C 3557/4885 |
| US-10961396-B2 | Methine dyes | PNMT, TET1, PRMT5 | ADRA2A 3228/4885ADRA2B 3637/4885ADRA2C 3045/4885 |
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | ADRA2A 154/4885ADRA2B 108/4885ADRA2C 258/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | ADRA2A 154/4885ADRA2B 108/4885ADRA2C 258/4885 |
| US-20240101560-A1 | NITROGENOUS HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES | NES, NCL, NPM1 | ADRA2A 3325/4885ADRA2B 3742/4885ADRA2C 3019/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | ADRA2A 1876/4885ADRA2B 2047/4885ADRA2C 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.